Muzastotug
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Muzastotug
- adg126
- ADG126
- immunoglobulin g1 anti human cytotoxic t lymphocyte associated protein 4 human monoclonal adg126 γ1 chain disulfide with prodomain peptide synthetic masking moiety and protease cleavable moiety fusion protein with human monoclonal adg126 κ chain dimer
- immunoglobulin g1 kappa anti homo sapiens ctla4 cytotoxic t lymphocyte associated protein 4 ctla 4 cd152 monoclonal antibody with cleavable prodomain gamma1 heavy chain 1 446 vh homo sapiens ighv3 7 01 77 8 ighd ighj4 01 100 cdr imgt 9 7 9 26 34 52 58 97 105 1 116 homo sapiens ighg1 01 100 g1m17 1 ch1 k120 d12 l14 ch1 k120 213 117 214 hinge 1 15 215 229 ch2 230 339 ch3 d12 355 l14 357 340 444 chs 445 446 117 446 219 256 disulfide with kappa light chain 1 256 cleavable prodomain 1 41 fused to v kappa homo sapiens igkv1 13 02 85 3 igkj1 01 100 cdr imgt 7 3 9 68 74 92 94 131 139 42 149 homo sapiens igkc 01 100 km3 a45 1 195 v101 233 150 256 dimer 225 225 228 228 bisdisulfide produced in chinese hamster ovary cho cells cell line cho k1 glycoform alfa
- immunoglobulin G1- kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody with cleavable prodomain; gamma1 heavy chain (1-446) [VH (Homo sapiens IGHV3-7*01 (77.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [9.7.9] (26-34.52-58.97-105)) (1-116) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (213) (117-214), hinge 1-15 (215-229), CH2 (230-339), CH3 D12 (355), L14 (357) (340-444), CHS (445-446)) (117-446)], (219-256')-disulfide with kappa light chain (1'-256') [cleavable prodomain (1'-41') fused to V-KAPPA (Homo sapiens IGKV1-13*02 (85.3%) -IGKJ1*01 (100%), CDR-IMGT [7.3.9] (68-74.92-94.131-139)) (42'-149') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (195), V101 (233) (150'-256')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
- Immunoglobulin G1, anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal ADG126 γ1-chain), disulfide with prodomain peptide (synthetic masking moiety and protease-cleavable moiety) fusion protein with human monoclonal ADG126 κ-chain, dimer
- muzastotug
- Muzastotug
- Muzastotug (immunoglobulin G1-kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], humanized monoclonal antibody with cleavable prodomain)
- muzastotug [INN]
- Muzastotug [WHO-DD]
- muzastotug immunoglobulin g1 kappa anti homo sapiens ctla4 cytotoxic t lymphocyte associated protein 4 ctla 4 cd152 humanized monoclonal antibody with cleavable prodomain
- muzastotug inn
- muzastotug who dd
- CAS registry numbers
- 2750031-18-4
- ChEMBL ID
- CHEMBL5314754
- FDA ingredient codes (UNII)
- 4L1XJF3HGL
- First in class
- No
- Orphan designation
- No
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Liver Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002691
- Subject identifier
- D008113
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 1
- NCT04524871
- NCT05405595
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 64'-130' $ 64'''-130''' $ 143-199 $ 143''-199'' $ 176'-236' $ 176'''-236''' $ 219-256' $ 219''-256''' $ 225-225'' $ 228-228'' $ 260-320 $ 260''-320'' $ 366-424 $ 366''-424''
- Component
- Light chain
- Type
- Protein
- Sequence
- EVGSYPNPSSDCVPYYYACAYSGRSAGGGGTPLGLAGSGGSDIQLTQSPSSLSASVGDRVTITCRASQSVRGRFLAWYQQKPGKAPKLLIYDASNRATGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSSWPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 296 $ 296''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYHWSWIRQAPGKGLEWLARIDWDDDKYYSTSLKSRLTISRDNSKNTLYLQLNSLRAEDTAVYYCARSYVYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Related records
Trials (7)
- A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
- Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
- Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
In development for (2)
- Liver cancer Phase 1
- Neoplasm Phase 2